The short answer: two ratios with different denominators
A certificate reading 99 percent purity and a vial reading 5 milligrams can both be accurate while the vial holds under 4 milligrams of the peptide named on it. Neither number is lying. They are measuring different things. Purity is a ratio taken within the peptide-related material. Net peptide content is a ratio taken against the entire mass of powder that was weighed into the vial.
The difference sits entirely in the denominator. A reversed-phase HPLC purity figure divides the area of the target peak by the total integrated peak area of everything the detector saw and the software counted. Every term in that fraction is a peptide. Water is not in it. Trifluoroacetate is not in it. Sodium chloride carried through from a buffer step is not in it. Those materials are not impurities that got a low score; they are outside the scoring system.
Net peptide content asks the question purity never asks: of the total mass in this vial, what fraction is peptide at all? For a lyophilised peptide isolated as a trifluoroacetate salt, that answer commonly falls somewhere between about 70 and 90 percent. It is not derivable from a chromatogram. It requires a separate assay, and on most research-grade certificates it is simply absent.
What an HPLC purity percentage actually counts
The standard determination runs the sample down a reversed-phase column on a water and acetonitrile gradient, usually with about 0.1 percent trifluoroacetic acid as the ion-pairing agent, and monitors ultraviolet absorbance at 214 or 220 nanometres. That wavelength is chosen because the peptide bond itself absorbs there, so the detector responds to backbone rather than to any particular side chain. The reported purity is the area of the main peak as a percentage of total integrated area.
That construction carries an assumption worth naming: that every species in the chromatogram gives the same detector response per unit mass. It does not. A truncated sequence missing several residues has fewer amide bonds, and so absorbs less at 214 nanometres per unit mass than the full-length product. It occupies less area than its mass share deserves. Area percent quietly flatters the main peak whenever the impurities are shorter than the target.
Several categories of material never enter the calculation at all. Species with no meaningful absorbance at the detection wavelength contribute nothing. Unretained material eluting in the void volume is routinely excluded from integration. Anything that binds irreversibly to the stationary phase, aggregated peptide included, never appears. And a diastereomer or a deamidated form that co-elutes with the target is counted as target.
Purity also says nothing about identity. A preparation can be 99 percent one peptide while that peptide is not the one on the label. Mass spectrometry, reporting an observed mass against the calculated mass for the intended sequence, is what closes that gap, and a purity figure presented without it answers a question nobody asked.
Where the rest of the mass went
Solid-phase synthesis ends by cleaving the finished chain from its resin with a strong acid, which in Fmoc chemistry is almost always trifluoroacetic acid. The crude material is then purified by reversed-phase HPLC using a mobile phase that also contains trifluoroacetic acid, and the collected fractions are lyophilised straight from that eluent. Trifluoroacetate is not a contaminant that slipped in. It is a structural consequence of how the peptide was made and purified.
It binds where the peptide carries positive charge. In an acidic mobile phase the basic sites are protonated, so each free alpha-amino terminus, each lysine side chain, each arginine and each histidine can pair with a trifluoroacetate ion. That anion weighs 113 daltons. How many of them a sequence carries is set by how many such sites it has, which is a property of the sequence itself rather than of the manufacturer's care.
Water is the next term. A lyophilised cake retains residual moisture, and trifluoroacetate salts of peptides are hygroscopic enough to take on more from the air whenever a vial is opened. Karl Fischer titration is the assay that quantifies it. Residual acetonitrile from the gradient, and inorganic salt carried through from any buffer exchange, account for most of what remains.
The arithmetic on a five milligram vial
Take a vial labelled 5 milligrams whose certificate reads 99 percent purity, and suppose the powder is 15 percent trifluoroacetate and 5 percent water by mass. Those two terms are 0.75 and 0.25 milligrams. That leaves 4.00 milligrams of peptide-related material, which is a net peptide content of 80 percent. The purity figure then applies to that 4.00 milligrams, not to the 5. Four times 0.99 gives 3.96 milligrams of the peptide named on the label.
The gap between 5 and 3.96 milligrams is 1.04 milligrams, or about 21 percent of what the label says. Split it by cause and the proportion is stark. Net peptide content accounts for 1.00 milligram of the shortfall. Purity accounts for 0.04. The number printed in large type on the certificate explains one twenty-sixth of the discrepancy. The number printed nowhere explains the other twenty-five.
Now run the same arithmetic on a less impressive certificate. A vial reporting 95 percent purity whose supplier also states 95 percent net peptide content holds 5 times 0.95 times 0.95, or 4.51 milligrams. It contains more of the named peptide than the 99 percent vial does, by roughly 14 percent. Ranked on the published number it looks worse. Ranked on mass of peptide it is better.
This is why the two figures cannot be traded against each other. They multiply. A certificate reporting only one of them has reported one factor of a product and left the other unstated, and the unstated factor is almost always the one with the wider range.
Why the same counterion costs a small peptide more
The counterion's share of the mass follows a simple expression: n times 113, divided by the peptide's molecular weight plus n times 113, where n is the number of bound trifluoroacetate ions. Because the peptide's molecular weight sits in the denominator while the counterion mass does not scale with it, the same chemistry takes a very different bite out of a tripeptide than out of a forty-residue chain.
GHK is glycyl-histidyl-lysine, a molecular weight of 340.4 daltons, with three protonatable sites between its amino terminus, its histidine imidazole and its lysine side chain. Suppose it carries two trifluoroacetates. That is 226 daltons of counterion against 340.4 daltons of peptide, for a total of 566.4. The peptide is 60 percent of that mass and the counterion is 40 percent, before a single milligram of water is counted.
Thymosin beta-4 is a 43-residue peptide of roughly 4,900 daltons. Two trifluoroacetates on that molecule are 226 daltons against a total near 5,189, or 4.4 percent. Identical counterion, identical synthesis chemistry, and close to a ninefold difference in how much of the vial it occupies. That sequence is lysine-rich and will in practice carry more than two; at six, the arithmetic gives 678 against 5,641, or about 12 percent.
The practical reading is that a milligram figure is a weaker statement about a small peptide than about a large one. Below about a thousand daltons the counterion is a first-order term in the mass rather than a rounding error, and a certificate that omits net peptide content is omitting proportionally more information.
GHK-Cu, where the metal is on the label too
The copper complex compounds the problem in a way that is arithmetic rather than carelessness. The GHK tripeptide is 340.4 daltons. A copper atom adds about 63.5. The complex therefore weighs roughly 404 daltons, of which copper is close to 16 percent. A perfectly pure, perfectly stoichiometric preparation with no water and no counterion at all still cannot exceed roughly 84 percent peptide by mass, because the remaining 16 percent is metal by design.
That makes the label ambiguous in a specific way. A vial marked 50 milligrams may mean 50 milligrams of the complex, in which case the tripeptide portion is around 42 milligrams, or 50 milligrams of tripeptide supplied as a heavier mass of complex. Both conventions are in circulation, and a purity percentage distinguishes neither, because both preparations are the same substance and would give the same chromatogram.
There is a further question a purity figure cannot address at all: what fraction of the copper is genuinely complexed to the peptide rather than sitting alongside it as a separate salt, and what the copper to peptide stoichiometry actually is. Those are questions for elemental analysis and spectroscopy. Ultraviolet area percent at 214 nanometres was never going to see a metal ion.
The assays that would answer the question
Amino acid analysis is the reference method for peptide content. The sample is hydrolysed to its constituent amino acids, which are derivatised and quantified against calibrated standards, and the recovered amino acid mass is compared with the mass of powder that went in. It measures peptide directly and is indifferent to whatever the peptide happened to be packaged with.
Quantitative NMR against a certified internal standard gives content without hydrolysis, on the same sample that supplies structural confirmation. Fluorine-19 NMR is unusually useful here, because trifluoroacetate is normally the only fluorinated species present, so it can be quantified directly rather than inferred from a difference. Ion chromatography reaches the same endpoint by another route, and identifies the counterion rather than assuming which one it is.
Water comes from Karl Fischer titration, residual solvents from headspace gas chromatography, and total nitrogen from combustion or Kjeldahl analysis as a cross-check on content. A certificate reporting peptide content, water, counterion and residual solvent lets a reader add the terms up and see whether the mass balance closes near 100 percent. One reporting a purity percentage alone offers nothing to add up.
How pharmacopoeial labelling handles the same problem
Regulated drug substance specifications separate these measurements rather than collapsing them. The ICH Q6A framework treats assay, which is content, as a different specification from related substances, which is the impurity profile, and both as different again from water content and residual solvents. Content is conventionally expressed on an anhydrous and solvent-free basis, precisely so that a change in moisture cannot masquerade as a change in potency.
Pharmacopoeial monographs for peptide drug substances follow the same logic, setting limits on the assay, identifying the counterion and capping how much of it is allowed, and specifying water separately. Someone reading an approved peptide product's label is reading a milligram figure defined against that scaffolding. It denotes a mass of active substance, not a mass of powder.
Research-use-only labelling carries none of those obligations. The phrase is a statement about intended use, not a description of analytical rigour, and it commits a supplier to no content specification whatsoever. The regulatory record around these particular compounds reflects the gap. BPC-157 sits among the nominated bulk drug substances judged to present significant safety concerns for compounding under section 503A, and thymosin beta-4 appears on the WADA Prohibited List among growth factors banned at all times. Neither status says anything about what a given powder weighs.
The counterion is not inert filler
It would be convenient to treat trifluoroacetate as dead weight, but the literature does not support that. Trifluoroacetate has documented effects in cell-based assays at concentrations reachable when a peptide is used at ordinary working concentrations as its TFA salt, which is why exchanging the salt form to acetate or hydrochloride is standard practice for material destined for biological experiments.
That matters for reading published work. If a study characterised a peptide as its acetate salt, and a differently sourced preparation of the same sequence is a trifluoroacetate salt, the two are not as interchangeable as the shared sequence suggests. A failure to reproduce a result then has an additional candidate explanation that the sequence alone would never have flagged.
The salt form also shifts solubility, hygroscopicity and storage behaviour. A certificate naming the counterion describes a property of the material; one that leaves it unnamed has left a variable undefined.
Reading two certificates side by side
Price per milligram is the comparison most readers actually want to make, and it cannot be made from purity. Two vials both labelled 5 milligrams at the same price, one at 80 percent net peptide content and one at 95 percent, differ by nearly a fifth in the real price per milligram of peptide. Nothing on a purity-only certificate would reveal that.
A complete document states the purity figure together with the method, wavelength and gradient it came from; an identity confirmation by mass spectrometry giving observed against calculated mass; net peptide content with the assay used to obtain it; water content; the counterion identified and quantified; and a lot number tying all of it to the material in hand.
The absence of most of that is common and is not by itself evidence of bad faith. A chromatogram with a purity number on it is a real measurement, honestly reported. It is simply a smaller measurement than the label implies, answering how clean the peptide fraction is while leaving how much peptide there is entirely open. Of the two numbers, the missing one is the larger.